About admin

This author has not yet filled in any details.
So far admin has created 519 blog entries.

Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page

Van Leeuwhoeck issues research note on Pharming (PHARM.AS): Turning the page. Click here to download this analyst report.  Summary: Pharming Group is a Dutch based biopharmaceutical company and one of the oldest publicly traded biotech companies in Europe. The company is focused on the development of recombinant proteins for therapeutic use. Pharming’s main platform is [...]

Pharming meldt additionele conversies van aflosbare converteerbare obligaties

Conversies resulteren in nieuwe uitgifte van 7.558.479 gewone aandelen volgend op eerdere conversies eind januari Totaalbedrag aan uitstaande aflosbare converteerbare obligaties afgenomen van €45 miljoen naar €39,7 miljoen Geen betaling in contanten benodigd voor eerste aflossingstermijn, terwijl ook de tweede termijn hiermee nagenoeg is voldaan Leiden, 3 februari 2017: Pharming Group N.V. (“Pharming” of “de [...]

Pharming announces additional conversions of its Amortizing Bonds

Total number of shares issued in the conversions is 7,558,479 ordinary shares Amount of Amortizing Bonds outstanding is reduced from €45.0 million to €39.7 million No cash payment was required in respect of the first instalment of the Bonds due on 1 February 2017 and the second installment due on 1 March 2017 has now [...]

STIFEL: Pharming Group N.V. (PHARM.NA, Buy) – New stock issue lowers Amortising Bond outstanding

A new analyst report from Stifel Financial Corp. is published. Stifel note 26 January 2017 Visit our Analyst Coverage & Reports page to read more reports from Stifel Financial Corp. Contact Sijmen de Vries, CEO: T: +31 (0)71 524 7400 “This update is for informational purposes only and is not viewed by Pharming to be of a [...]

Pharming meldt uitgifte van nieuwe aandelen door conversie van aflosbare converteerbare obligaties

Aantal uitgegeven aandelen bedraagt 10.823.881 Totaalbedrag aan uitstaande aflosbare converteerbare obligaties neemt af van €45 miljoen naar €41,9 miljoen Leiden, 26 januari 2017: Pharming Group N.V. (“Pharming” of “de Onderneming”) (EURONEXT: PHARM) maakt bekend dat het 10.823.881 nieuwe aandelen heeft uitgegeven aan houders van de aflosbare obligatielening 2017/18, en die een aantal van hun Obligaties [...]

Pharming announces issue of new stock as a result of conversion of Amortizing Bonds

Total number of shares issued in the conversions is 10,823,881 ordinary shares Amount of Amortizing Bonds outstanding is reduced from €45.0 million to €41.9 million Leiden, The Netherlands, 26 January 2017: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT: PHARM) today announced that it has issued 10,823,881 new shares to holders of the Amortizing Bonds due 2017/8 [...]

PHARM.AS: Increased Ruconest Focus Should Drive Upside

Biotech company Pharming Group NV announces a new analyst report from Roth Capital Partners. PHARM.AS: Increased Ruconest Focus Should Drive Upside Roth note 24 Jan 2017 Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners. Contact Sijmen de Vries, CEO: T: +31 524 7400 “This update is for informational purposes [...]

Europese Commissie breidt Marketingvergunning RUCONEST® uit met zelfstandige toediening

Toedienings-kits in de komende maanden beschikbaar in EU-markten EU goedkeuring volgt op eerdere goedkeuring in VS in 2014  Leiden, 16 januari 2017: Pharming Group N.V. (de “Onderneming”) (EURONEXT: PHARM) maakt bekend dat naar aanleiding van het eerdere positieve advies van het adviesorgaan (CHMP) van het Europese Geneesmiddelenbureau (EMA), de Europese Commissie uitbreiding van de marketingvergunning [...]

European Commission amends Marketing Authorisation for RUCONEST® to include self-administration

Administration kits to be available in EU markets during the coming months EU approval of self-administration follows US approval received in 2014 Leiden, The Netherlands, 16 January 2017: Pharming Group N.V. (the “Company”) (EURONEXT: PHARM) today announced that, following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP), the European Commission [...]

STIFEL: Pharming Group N.V. (PHARM.NA, Buy) – Back in control of its destiny; Resuming Coverage Following Research Restriction

STIFEL: Pharming Group N.V. (PHARM.NA, Buy) - Back in control of its destiny; Resuming Coverage Following Research Restriction A new analyst report from Stifel Financial Corp. is published. Stifel note 09 December 2016 Visit our Analyst Coverage & Reports page to read more reports from Stifel Financial Corp. Contact Sijmen de Vries, CEO: T: +31 (0)71 524 [...]